Guerbet (XPAR:GBT) FFO


XPAR:GBT Guerbet SA XPAR:GBT
66 GF Score
Price €9.00
GF Value €19.65
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Guerbet FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:GBT
66GF Score
Guerbet SA XPAR:GBT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Guerbet (XPAR:GBT) Overvalued in 2026?

Based on GuruFocus' analysis, Guerbet stock appears to be undervalued. The current stock price of €9.00 is trading 54.2% below its estimated GF Value™ of €19.65. GuruFocus considers Guerbet to be Possible Value Trap.

Key valuation signals for XPAR:GBT:

  • FFO:
  • GF Value™: €19.65 vs. price of €9.00 (54.2% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the XPAR:GBT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guerbet Business Description

Other Exchanges 0ELV:UK4G8:Germany
Address 15 rue des Vanesses, Zone Paris Nord II, Villepinte, FRA, 93420
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
66GF Score

Get the complete analysis for XPAR:GBT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.00
Price
€19.65
GF Value